The combination of LILRB4-targeting NK cell engagers and cGAS-STING agonists enhances the anti-multiple myeloma immune activity of NK cells.
Although significant progress has been made in immune-targeted therapy for multiple myeloma (MM), it remains highly recurrent and incurable. Consequently, there is still an urgent need to develop more effective strategies against the recurrent and refractory tumor subsets. LILRB4, which is expressed...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Public Library of Science (PLoS)
2025-01-01
|
| Серии: | PLoS ONE |
| Online-ссылка: | https://doi.org/10.1371/journal.pone.0339375 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|